Kura Oncology (KURA) Total Current Liabilities (2010 - 2026)
Kura Oncology (KURA) reported Total Current Liabilities of $101.5 million for Q1 2026, up 13.07% year-over-year from $89.8 million in Q1 2025, and down 13.23% on a QoQ basis from $117.0 million in Q4 2025.
Kura Oncology (KURA) has 17 years of Total Current Liabilities data on file, last reported at $101.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 13.07% year-over-year to $101.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.5 million (up 13.07% YoY) and the FY2025 annual result came in at $117.0 million, up 48.61% from the prior year.
- Total Current Liabilities retreated to $101.5 million in Q1 2026 per KURA's latest filing, from $117.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $121.3 million in Q3 2025 and bottomed at $17.7 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $33.5 million (2024), against an average of $53.6 million.
- The widest annual swing landed in 2022, when Total Current Liabilities decreased 29.49%; it then surged 220.39% in 2025.
- Tracing KURA's Total Current Liabilities over 5 years: stood at $24.1 million in 2022, then jumped by 46.58% to $35.3 million in 2023, then surged by 123.21% to $78.7 million in 2024, then surged by 48.61% to $117.0 million in 2025, then declined by 13.23% to $101.5 million in 2026.
- Per Business Quant, the three latest KURA Total Current Liabilities figures stand at $101.5 million (Q1 2026), $117.0 million (Q4 2025), and $121.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 101.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.50 Mn |
| Dec 31, 2025 | 116.97 Mn |
| Sep 30, 2025 | 121.30 Mn |
| Jun 30, 2025 | 107.17 Mn |
| Mar 31, 2025 | 89.77 Mn |
| Dec 31, 2024 | 78.71 Mn |
| Sep 30, 2024 | 40.37 Mn |
| Jun 30, 2024 | 33.45 Mn |
| Mar 31, 2024 | 32.27 Mn |
| Dec 31, 2023 | 35.26 Mn |
| Sep 30, 2023 | 27.53 Mn |
| Jun 30, 2023 | 23.90 Mn |
| Mar 31, 2023 | 19.23 Mn |
| Dec 31, 2022 | 24.06 Mn |
| Sep 30, 2022 | 24.75 Mn |
| Jun 30, 2022 | 17.87 Mn |
| Mar 31, 2022 | 17.73 Mn |
| Dec 31, 2021 | 22.46 Mn |
| Sep 30, 2021 | 21.93 Mn |
| Jun 30, 2021 | 21.29 Mn |
| Mar 31, 2021 | 25.14 Mn |
| Dec 31, 2020 | 26.02 Mn |
| Sep 30, 2020 | 21.71 Mn |
| Jun 30, 2020 | 18.55 Mn |
| Mar 31, 2020 | 14.55 Mn |
| Dec 31, 2019 | 15.56 Mn |
| Sep 30, 2019 | 13.11 Mn |
| Jun 30, 2019 | 11.23 Mn |
| Mar 31, 2019 | 12.14 Mn |
| Dec 31, 2018 | 13.62 Mn |
| Sep 30, 2018 | 12.91 Mn |
| Jun 30, 2018 | 12.58 Mn |
| Mar 31, 2018 | 11.35 Mn |
| Dec 31, 2017 | 10.03 Mn |
| Sep 30, 2017 | 7.56 Mn |
| Jun 30, 2017 | 5.08 Mn |
| Mar 31, 2017 | 4.12 Mn |
| Dec 31, 2016 | 5.45 Mn |
| Sep 30, 2016 | 5.27 Mn |
| Jun 30, 2016 | 4.38 Mn |
| Mar 31, 2016 | 4.31 Mn |
| Dec 31, 2015 | 5.06 Mn |
| Sep 30, 2015 | 4.71 Mn |
| Jun 30, 2015 | 3.60 Mn |
| Mar 31, 2015 | 5.53 Mn |
| Dec 31, 2014 | 3.02 Mn |
| Mar 31, 2013 | 105,345.00 |
| Dec 31, 2012 | 103,648.00 |
| Sep 30, 2012 | 97,145.00 |
| Jun 30, 2012 | 95,402.00 |
| Mar 31, 2012 | 97,771.00 |
| Dec 31, 2011 | 74,751.00 |
| Sep 30, 2011 | 69,677.00 |
| Jun 30, 2011 | 68,385.00 |
| Mar 31, 2011 | 74,751.00 |
| Dec 31, 2010 | 70,389.00 |